OBJECTIVES: The goal of this study was to guide bone marrow-derived human mesenchymal stem cells (hMSCs) into a cardiac progenitor phenotype and assess therapeutic benefit in chronic myocardial infarction. BACKGROUND: Adult stem cells, delivered in their naïve state, demonstrate a limited benefit in patients with ischemic heart disease. Pre-emptive lineage pre-specification may optimize therapeutic outcome. METHODS: hMSC were harvested from a coronary artery disease patient cohort. A recombinant cocktail consisting of transforming growth factor-beta(1), bone morphogenetic protein-4, activin A, retinoic acid, insulin-like growth factor-1, fibroblast growth factor-2, alpha-thrombin, and interleukin-6 was formulated to engage hMSC into cardiopoiesis. Derived hMSC were injected into the myocardium of a nude infarcted murine model and followed over 1 year for functional and structural end points. RESULTS: Although the majority of patient-derived hMSC in their native state demonstrated limited effect on ejection fraction, stem cells from rare individuals harbored a spontaneous capacity to improve contractile performance. This reparative cytotype was characterized by high expression of homeobox transcription factor Nkx-2.5, T-box transcription factor TBX5, helix-loop-helix transcription factor MESP1, and myocyte enhancer factor MEF2C, markers of cardiopoiesis. Recombinant cardiogenic cocktail guidance secured the cardiopoietic phenotype across the patient cohort. Compared with unguided counterparts, cardiopoietic hMSC delivered into infarcted myocardium achieved superior functional and structural benefit without adverse side effects. Engraftment into murine hearts was associated with increased human-specific nuclear, sarcomeric, and gap junction content along with induction of myocardial cell cycle activity. CONCLUSIONS: Guided cardiopoiesis thus enhances the therapeutic benefit of bone marrow-derived hMSC in chronic ischemic cardiomyopathy. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: The goal of this study was to guide bone marrow-derived human mesenchymal stem cells (hMSCs) into a cardiac progenitor phenotype and assess therapeutic benefit in chronic myocardial infarction. BACKGROUND: Adult stem cells, delivered in their naïve state, demonstrate a limited benefit in patients with ischemic heart disease. Pre-emptive lineage pre-specification may optimize therapeutic outcome. METHODS:hMSC were harvested from a coronary artery diseasepatient cohort. A recombinant cocktail consisting of transforming growth factor-beta(1), bone morphogenetic protein-4, activin A, retinoic acid, insulin-like growth factor-1, fibroblast growth factor-2, alpha-thrombin, and interleukin-6 was formulated to engage hMSC into cardiopoiesis. Derived hMSC were injected into the myocardium of a nude infarctedmurine model and followed over 1 year for functional and structural end points. RESULTS: Although the majority of patient-derived hMSC in their native state demonstrated limited effect on ejection fraction, stem cells from rare individuals harbored a spontaneous capacity to improve contractile performance. This reparative cytotype was characterized by high expression of homeobox transcription factor Nkx-2.5, T-box transcription factor TBX5, helix-loop-helix transcription factor MESP1, and myocyte enhancer factor MEF2C, markers of cardiopoiesis. Recombinant cardiogenic cocktail guidance secured the cardiopoietic phenotype across the patient cohort. Compared with unguided counterparts, cardiopoietic hMSC delivered into infarcted myocardium achieved superior functional and structural benefit without adverse side effects. Engraftment into murine hearts was associated with increased human-specific nuclear, sarcomeric, and gap junction content along with induction of myocardial cell cycle activity. CONCLUSIONS: Guided cardiopoiesis thus enhances the therapeutic benefit of bone marrow-derived hMSC in chronic ischemic cardiomyopathy. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: Carmen Perez-Terzic; Atta Behfar; Annabelle Méry; Jan M A van Deursen; Andre Terzic; Michel Pucéat Journal: Circ Res Date: 2003-01-30 Impact factor: 17.367
Authors: A M Wobus; G Kaomei; J Shan; M C Wellner; J Rohwedel; B Fleischmann; H A Katus; J Hescheler; W M Franz Journal: J Mol Cell Cardiol Date: 1997-06 Impact factor: 5.000
Authors: Yuehua Jiang; Balkrishna N Jahagirdar; R Lee Reinhardt; Robert E Schwartz; C Dirk Keene; Xilma R Ortiz-Gonzalez; Morayma Reyes; Todd Lenvik; Troy Lund; Mark Blackstad; Jingbo Du; Sara Aldrich; Aaron Lisberg; Walter C Low; David A Largaespada; Catherine M Verfaillie Journal: Nature Date: 2002-06-20 Impact factor: 49.962
Authors: Christine Mummery; Dorien Ward-van Oostwaard; Pieter Doevendans; Rene Spijker; Stieneke van den Brink; Rutger Hassink; Marcel van der Heyden; Tobias Opthof; Martin Pera; Aart Brutel de la Riviere; Robert Passier; Leon Tertoolen Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: Gabriele Plenz; Heike Eschert; Michael Erren; Thomas Wichter; Michael Böhm; Markus Flesch; Hans H Scheld; Mario C Deng Journal: J Am Coll Cardiol Date: 2002-05-01 Impact factor: 24.094
Authors: S D Bird; P A Doevendans; M A van Rooijen; A Brutel de la Riviere; R J Hassink; R Passier; C L Mummery Journal: Cardiovasc Res Date: 2003-05-01 Impact factor: 10.787
Authors: James D Richardson; Adam J Nelson; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley; Peter J Psaltis Journal: Stem Cell Rev Rep Date: 2013-06 Impact factor: 5.739
Authors: Georg Siegel; Petra Krause; Stefanie Wöhrle; Patrick Nowak; Miriam Ayturan; Torsten Kluba; Bernhard R Brehm; Birgid Neumeister; David Köhler; Peter Rosenberger; Lothar Just; Hinnak Northoff; Richard Schäfer Journal: Stem Cells Dev Date: 2012-03-13 Impact factor: 3.272
Authors: Atta Behfar; Jean-Pierre Latere; Jozef Bartunek; Christian Homsy; Dorothee Daro; Ruben J Crespo-Diaz; Paul G Stalboerger; Valerie Steenwinckel; Aymeric Seron; Margaret M Redfield; Andre Terzic Journal: Circ Cardiovasc Interv Date: 2013-12-10 Impact factor: 6.546
Authors: Ivan Martin; Helen Baldomero; Chiara Bocelli-Tyndall; Maximilian Y Emmert; Simon P Hoerstrup; Hilary Ireland; Jakob Passweg; Alan Tyndall Journal: Tissue Eng Part A Date: 2013-11-08 Impact factor: 3.845